These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475 [TBL] [Abstract][Full Text] [Related]
28. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650 [TBL] [Abstract][Full Text] [Related]
29. Relative biological effectiveness of alpha-particle emitters in vivo at low doses. Howell RW; Azure MT; Narra VR; Rao DV Radiat Res; 1994 Mar; 137(3):352-60. PubMed ID: 8146279 [TBL] [Abstract][Full Text] [Related]
30. Application of Cerenkov radiation for the assay of 226Ra in natural water. al-Masri MS; Blackburn R Sci Total Environ; 1995 Dec; 173-174():53-9. PubMed ID: 8560231 [TBL] [Abstract][Full Text] [Related]
31. Diffusing alpha-emitters radiation therapy: approximate modeling of the macroscopic alpha particle dose of a point source. Arazi L Phys Med Biol; 2020 Jan; 65(1):015015. PubMed ID: 31766047 [TBL] [Abstract][Full Text] [Related]
32. The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma. Rotmensch J; Atcher RW; Hines J; Grdina D; Schwartz JS; Toohill M; Herbst AL Am J Obstet Gynecol; 1989 Apr; 160(4):789-97. PubMed ID: 2712112 [TBL] [Abstract][Full Text] [Related]
33. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783 [TBL] [Abstract][Full Text] [Related]
34. Engineered liposomes for potential alpha-particle therapy of metastatic cancer. Sofou S; Thomas JL; Lin HY; McDevitt MR; Scheinberg DA; Sgouros G J Nucl Med; 2004 Feb; 45(2):253-60. PubMed ID: 14960644 [TBL] [Abstract][Full Text] [Related]
35. An electrochemical generator for the continual supply of Forrester R; Dutech G; Akin A; Fassbender ME; Mastren T Nucl Med Biol; 2024; 136-137():108941. PubMed ID: 39002499 [TBL] [Abstract][Full Text] [Related]
36. Argonne-Utah studies of 224Ra endosteal surface dosimetry. Schlenker RA; Smith JM Strahlentherapie Sonderb; 1985; 80():93-8. PubMed ID: 3006291 [No Abstract] [Full Text] [Related]
37. Production of high-purity radium-223 from legacy actinium-beryllium neutron sources. Soderquist CZ; McNamara BK; Fisher DR Curr Radiopharm; 2012 Jul; 5(3):244-52. PubMed ID: 22697483 [TBL] [Abstract][Full Text] [Related]
38. Cellular dose conversion factors for alpha-particle--emitting radionuclides of interest in radionuclide therapy. Hamacher KA; Den RB; Den EI; Sgouros G J Nucl Med; 2001 Aug; 42(8):1216-21. PubMed ID: 11483682 [TBL] [Abstract][Full Text] [Related]
39. An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation. McDevitt MR; Finn RD; Sgouros G; Ma D; Scheinberg DA Appl Radiat Isot; 1999 May; 50(5):895-904. PubMed ID: 10214708 [TBL] [Abstract][Full Text] [Related]
40. An improved tungsten-178/tantalum-178 generator system for high volume clinical applications. Lacy JL; Ball ME; Verani MS; Wiles HB; Babich JW; LeBlanc AD; Stabin M; Bolomey L; Roberts R J Nucl Med; 1988 Sep; 29(9):1526-38. PubMed ID: 3137317 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]